دورية أكاديمية
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
| العنوان: | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease |
|---|---|
| المؤلفون: | Vergallo A., Megret L., Lista S., Cavedo E., Zetterberg H., Blennow K., Vanmechelen E., De Vos A., Habert M. -O., Potier M. -C., Dubois B., Neri C., Hampel H., Bakardjian H., Benali H., Bertin H., Bonheur J., Boukadida L., Boukerrou N., Chiesa P., Colliot O., Dubois M., Epelbaum S., Gagliardi G., Genthon R., Habert M. O., Houot M., Kas A., Lamari F., Levy M., Metzinger C., Mochel F., Nyasse F., Poisson C., Revillon M., Santos A., Andrade K. S., Sole M., Surtee M., de Schotten M T., Younsi N., Aguilar L. F., Babiloni C., Baldacci F., Benda N., Black K. L., Bokde A. L. W., Bonuccelli U., Broich K., Cacciola F., Castrillo J., Ceravolo R., Chiesa P. A., Corvol J. -C., Cuello A. C., Cummings J. L., Depypere H., Duggento A., Escott-Price V., Federoff H., Ferretti M. T., Fiandaca M., Frank R. A., Garaci F., Geerts H., Giorgi F. S., Graziani M., Haberkamp M., Herholz K., Karran E., Kim S. H., Koronyo Y., Koronyo-Hamaoui M., Langevin T., Lehericy S., Lorenceau J., Mango D., Mapstone M., Nistico R., O'Bryant S. E., Perry G., Ritchie C., Rossi S., Saidi A., Santarnecchi E., Schneider L. S., Sporns O., Toschi N., Verdooner S. R., Villain N., Welikovitch L. A., Woodcock J., Younesi E. |
| المساهمون: | Vergallo, A., Megret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., De Vos, A., Habert, M. -O., Potier, M. -C., Dubois, B., Neri, C., Hampel, H., Bakardjian, H., Benali, H., Bertin, H., Bonheur, J., Boukadida, L., Boukerrou, N., Chiesa, P., Colliot, O., Dubois, M., Epelbaum, S., Gagliardi, G., Genthon, R., Habert, M. O., Houot, M., Kas, A., Lamari, F., Levy, M., Metzinger, C., Mochel, F., Nyasse, F., Poisson, C., Revillon, M., Santos, A., Andrade, K. S., Sole, M., Surtee, M., de Schotten M, T., Younsi, N., Aguilar, L. F., Babiloni, C., Baldacci, F., Benda, N., Black, K. L., Bokde, A. L. W., Bonuccelli, U., Broich, K., Cacciola, F., Castrillo, J., Ceravolo, R., Chiesa, P. A., Corvol, J. -C., Cuello, A. C., Cummings, J. L., Depypere, H., Duggento, A., Escott-Price, V., Federoff, H., Ferretti, M. T., Fiandaca, M., Frank, R. A., Garaci, F., Geerts, H., Giorgi, F. S., Graziani, M., Haberkamp, M., Herholz, K., Karran, E., Kim, S. H., Koronyo, Y., Koronyo-Hamaoui, M., Langevin, T., Lehericy, S., Lorenceau, J., Mango, D., Mapstone, M., Nistico, R., O'Bryant, S. E., Perry, G., Ritchie, C., Rossi, S., Saidi, A., Santarnecchi, E., Schneider, L. S., Sporns, O., Toschi, N., Verdooner, S. R., Villain, N., Welikovitch, L. A., Woodcock, J., Younesi, E. |
| سنة النشر: | 2019 |
| المجموعة: | Università degli Studi di Siena: USiena air |
| مصطلحات موضوعية: | Alzheimer's disease, Amyloid PET, Classification and regression trees (CART), Machine learning, Plasma amyloid β, Simoa immunoassay, Subjective memory complainers |
| الوصف: | Introduction: Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. Methods: We investigated whether plasma concentrations of the Aβ1–40/Aβ1–42 ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-a-priori hypothesis study using machine learning. Results: The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ1–40/Aβ1–42 ratio. The accuracy is not affected by the apolipoprotein E (APOE)ε4 allele, sex, or age. Discussion: Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1–40/Aβ1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design. © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31113759; info:eu-repo/semantics/altIdentifier/wos/WOS:000470084500004; volume:15; issue:6; firstpage:764; lastpage:775; numberofpages:12; journal:ALZHEIMER'S & DEMENTIA; http://hdl.handle.net/11365/1124330Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85065799769 |
| DOI: | 10.1016/j.jalz.2019.03.009 |
| الإتاحة: | https://doi.org/10.1016/j.jalz.2019.03.009Test http://hdl.handle.net/11365/1124330Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.818D0B11 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jalz.2019.03.009 |
|---|